Meeting
2020 ASCO Virtual Scientific Program
DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
Authors
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center, Houston, TX
Shannon Neville Westin , Kathleen N. Moore , Els Van Nieuwenhuysen , Amit M. Oza , Linda R. Mileshkin , Aikou Okamoto , Akiko Suzuki , Kassondra Meyer , Laura Barker , Joon Rhee , Ignace Vergote
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Clinical Trial Registration Number
2019-004112-60
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS6108)
DOI
10.1200/JCO.2020.38.15_suppl.TPS6108
Abstract #
TPS6108
Poster Bd #
279
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
First Author: Christian Marth
Poster
2022 ASCO Annual Meeting
Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).
First Author: Jean Emmanuel Kurtz
Poster
2022 ASCO Annual Meeting
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
First Author: Florian Heitz
Poster
2020 ASCO Virtual Scientific Program
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
First Author: Domenica Lorusso